Revolution Medicines (RVMD) SVP Jeff Cislini Sells 765 Shares

What Happened
Jeff Cislini, SVP & General Counsel of Revolution Medicines (RVMD), sold 765 shares on September 25, 2026, at $207.32 per share, generating approximately $158,600. The filing reports the sale was made pursuant to a 10b5-1 trading plan adopted May 22, 2026.

Key Details

• Transaction date and price: 2026-09-25 — 765 shares @ $207.32 (total ≈ $158,600).
• Transaction type: Sale (S), executed under a 10b5-1 trading plan (footnote F1).
• Holdings noted: filing indicates holdings include 37,088 restricted stock units (footnote F2); exact total shares owned following the transaction not specified in the provided data.
• Filing date and timeliness: Form 4 filed 2026-09-29 — within the standard two-business-day filing window.

Context
This was a pre-scheduled sale under a 10b5-1 plan, which generally means the transaction was automated according to a plan adopted earlier and is less likely to reflect contemporaneous, undisclosed views of company prospects. Sales by insiders can be routine (liquidity, diversification, tax planning) and should be weighed alongside other insider activity and company fundamentals.